Talk:Valproic acid: Difference between revisions

From Citizendium
Jump to navigation Jump to search
imported>Robert Badgett
(New page: {{subpages}})
 
imported>Howard C. Berkowitz
Line 1: Line 1:
{{subpages}}
{{subpages}}
== Acid and sodium salt ==
First, I'd like to find a better source on the indications for use of valproic acid versus valproate sodium. My clinical experience, however, is much more with the use in mood disorders and neurogenic pain than for convulsive disorders, and when I've asked some of the physicians prescribing why the salt and not the acid, I've never gotten an especially clear answer.
Second, raises a general question for pharmacology articles. What range of relatively small molecular variants should be under the same article? Some variants seem simply for manufacturing or marketing, while others actually do affect bioavailability.
In turn, this leads to the question of when it is best to address, as a family, therapeutic agents where there may be both prodrug and active metabolite preparations.  This may be more of a Forum question, but I thought I would start here. [[User:Howard C. Berkowitz|Howard C. Berkowitz]] 12:08, 29 June 2008 (CDT)

Revision as of 11:08, 29 June 2008

This article is developing and not approved.
Main Article
Discussion
Related Articles  [?]
Bibliography  [?]
External Links  [?]
Citable Version  [?]
 
To learn how to update the categories for this article, see here. To update categories, edit the metadata template.
 Definition An anticonvulsant medication. [d] [e]
Checklist and Archives
 Workgroup category Health Sciences [Please add or review categories]
 Talk Archive none  English language variant American English

Acid and sodium salt

First, I'd like to find a better source on the indications for use of valproic acid versus valproate sodium. My clinical experience, however, is much more with the use in mood disorders and neurogenic pain than for convulsive disorders, and when I've asked some of the physicians prescribing why the salt and not the acid, I've never gotten an especially clear answer.

Second, raises a general question for pharmacology articles. What range of relatively small molecular variants should be under the same article? Some variants seem simply for manufacturing or marketing, while others actually do affect bioavailability.

In turn, this leads to the question of when it is best to address, as a family, therapeutic agents where there may be both prodrug and active metabolite preparations. This may be more of a Forum question, but I thought I would start here. Howard C. Berkowitz 12:08, 29 June 2008 (CDT)